Retatrutide 15mg

£150.00

Pound sterling (£) - GBP

Pound sterling (£) - GBP
Euro (€) - EUR
United States dollar ($) - USD

Description

Retatrutide 15mg

This information is for general knowledge and should not be taken as medical advice. Consult with a healthcare provider before starting any new supplement regimen.

Retatrutide: An Overview

Retatrutide is an investigational drug being studied for the treatment of obesity and related metabolic disorders. It is a triple-receptor agonist that targets glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors. This action is intended to reduce appetite, increase energy expenditure, and potentially improve metabolic health.

Mechanism of Action

Retatrutide is designed to mimic the effects of natural hormones involved in regulating hunger, satiety, and metabolism.

GLP-1 receptor activation: This action is associated with increased insulin secretion, slowed gastric emptying, and reduced appetite.
GIP receptor activation: This can enhance insulin secretion in a glucose-dependent manner and may contribute to improved insulin sensitivity.
Glucagon receptor activation: This is linked to the mobilization of stored energy, increased metabolism, and the promotion of fat breakdown.

This combination of actions is thought to contribute to weight loss observed in clinical trials.

Dosing and Administration

Retatrutide is typically administered as a once-weekly subcutaneous injection. Dosage is often adjusted based on individual response, potentially starting at a lower dose and gradually increasing.

Clinical Trial Results (as of late 2024/early 2025)

Weight loss: Phase 2 clinical trials in adults with obesity have shown significant mean weight reductions over a period of weeks. In one trial, participants in a specific dose group experienced a substantial average weight loss over 48 weeks.
Other potential benefits: Trials have also suggested that Retatrutide may improve blood sugar control, reduce liver fat in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), and potentially mitigate cardiovascular risk factors.
Side effects: Common side effects are similar to other GLP-1 receptor agonists and primarily involve gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation. These are often mild to moderate and may decrease over time as the body adjusts.

FDA Approval Status

Retatrutide is not currently approved by the FDA and remains under clinical investigation. Phase 3 trials are ongoing to evaluate its long-term safety and efficacy. An FDA submission is anticipated in 2026, with potential retail availability in 2027 if trials are successful.

Product Details

Retatrutide is not currently FDA-approved and should not be used outside of clinical trials.
Potential users should be aware of possible side effects and discuss them with a healthcare professional.
The FDA has warned against obtaining Retatrutide through unofficial channels online due to the risk of counterfeit products and safety concerns.
Individuals seeking weight loss options should consult with a licensed healthcare provider to determine the safest and most effective approach for their individual needs.

Delivery and Returns

We offer complimentary express shipping.

Free returns are available worldwide. If your item is eligible for return, you have 30 days from the date you receive your order to follow this procedure.

See delivery and returns for more information.